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A bs tr ac t
Background
Profound hearing loss is a serious complication of neurofibromatosis type 2, a ge-
netic condition associated with bilateral vestibular schwannomas, benign tumors 
that arise from the eighth cranial nerve. There is no medical treatment for such 
tumors.
Methods
We determined the expression pattern of vascular endothelial growth factor (VEGF) 
and three of its receptors, VEGFR-2, neuropilin-1, and neuropilin-2, in paraffin-
embedded samples from 21 vestibular schwannomas associated with neurofibro-
matosis type 2 and from 22 sporadic schwannomas. Ten consecutive patients with 
neurofibromatosis type 2 and progressive vestibular schwannomas who were not 
candidates for standard treatment were treated with bevacizumab, an anti-VEGF 
monoclonal antibody. An imaging response was defined as a decrease of at least 
20% in tumor volume, as compared with baseline. A hearing response was defined 
as a significant increase in the word-recognition score, as compared with baseline.
Results
VEGF was expressed in 100% of vestibular schwannomas and VEGFR-2 in 32% of 
tumor vessels on immunohistochemical analysis. Before treatment, the median an-
nual volumetric growth rate for 10 index tumors was 62%. After bevacizumab treat-
ment in the 10 patients, tumors shrank in 9 patients, and 6 patients had an imaging 
response, which was maintained in 4 patients during 11 to 16 months of follow-up. 
The median best response to treatment was a volumetric reduction of 26%. Three 
patients were not eligible for a hearing response; of the remaining seven patients, 
four had a hearing response, two had stable hearing, and one had progressive hear-
ing loss. There were 21 adverse events of grade 1 or 2.
Conclusions
VEGF blockade with bevacizumab improved hearing in some, but not all, patients 
with neurofibromatosis type 2 and was associated with a reduction in the volume 
of most growing vestibular schwannomas.
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Neurofibromatosis type 2 is a domi-nantly inherited genetic condition with a birth prevalence of 1 in 25,000.1 Bilateral 
vestibular schwannomas (also known as acoustic 
neuromas), which are benign tumors composed 
of neoplastic Schwann cells that arise from the 
eighth cranial nerve, are the hallmark of neuro-
fibromatosis 2. These tumors cause progressive 
hearing loss in most patients with neurofibroma-
tosis type 2, who commonly lose all functional 
hearing during early adulthood or middle age. 
Standard therapy for growing sporadic, unilateral 
vestibular schwannomas includes surgical remov-
al or radiation therapy. Both treatments usually 
achieve tumor control, but at the frequent cost of 
hearing loss in the affected ear.2,3
Treatment options are limited for patients with 
neurofibromatosis type 2 and a growing vestibu-
lar schwannoma ipsilateral to the only ear with 
hearing. Results of surgery and radiation ther-
apy for vestibular schwannomas associated with 
neurofibromatosis type 2 are worse than for 
sporadic tumors, because rates of tumor control 
are reduced and iatrogenic hearing loss is more 
frequent.4-6 Although the morbidity of active 
treatment can be prohibitively high, the conse-
quences of unchecked tumor growth (including 
progressive brain-stem compression) are also se-
vere. Currently, no medical treatments for tumors 
associated with neurofibromatosis type 2 are 
available, and a safe and effective treatment for 
these patients is needed.
Vascular endothelial growth factor (VEGF) is a 
critical mediator of tumor angiogenesis and ves-
sel permeability.7-9 VEGF and its receptor VEGFR-1 
have been detected in schwannomas, and in-
creased levels of these factors correlate with 
increased rates of tumor growth.10-14 Although 
schwannomas are not considered vascular tumors, 
the non–VEGF-related, antiangiogenic compound 
AGM-1470 inhibits angiogenesis and reduces the 
growth of nerve-sheath tumors in mouse mod-
els.15 The VEGF-neutralizing antibody bevacizu-
mab has been approved by the Food and Drug 
Administration for use in the treatment of can-
cers, but no studies have been performed in pa-
tients with neurofibromatosis type 2 or vestibu-
lar schwannomas.
Here we describe a retrospective study of 10 
consecutive patients with neurofibromatosis type 
2 and growing vestibular schwannomas who were 
treated with bevacizumab. We chose this agent 
on the basis of tumor immunohistochemical 
analyses suggesting a potential pathophysio-
logical role for the VEGF pathway in vestibular 
schwannomas. We provide radiologic and audio-
logic evidence that bevacizumab treatment of-
fered durable clinical benefit to some patients, 
including a reduction in tumor volume and an 
improvement in chronic hearing loss.
Me thods
Immunohistochemical Analyses
Paraffin-embedded tissue sections from 21 schwan-
nomas associated with neurofibromatosis type 2, 
22 sporadic schwannomas, and 9 normal spinal-
nerve roots were immunostained with the follow-
ing antibodies: CD31, VEGF, VEGFR-2, platelet-
derived growth factor receptor α (PDGFR-α), 
PDGFR-β, neuropilin-1, neuropilin-2, semaphorin 
3A, and semaphorin 3F. Semiquantitative analy-
sis was performed by two authors, who scored 
the intensity of tumor-cell and blood-vessel stain-
ing on a scale of 0 (no staining) to 3 (strong 
staining). A customized software analysis tool 
was used to determine the number of vessels, 
perimeter, the minor axis of best fitted ellipse 
(representative of vessel diameter), and the total 
surface covered by vascular spaces. The same 
method was used, with the substitution of either 
VEGFR-2 or neuropilin-2 labeling, to determine 
the proportion of vessels expressing these VEGF 
receptors (for details, see the Supplementary Ap-
pendix, available with the full text of this article 
at NEJM.org).
Selection of Patients
We offered bevacizumab on a compassionate-use 
basis to patients who fulfilled the clinical diag-
nostic criteria for neurofibromatosis type 2,16 
had evidence of progressive vestibular schwan-
nomas, and were considered poor candidates for 
surgery and radiation therapy or declined these 
treatments. Consecutive patients who met these 
criteria and had received at least one bevacizu-
mab dose as of August 1, 2008, were included in 
the analysis.
Clinical Evaluations
The intervals for clinical evaluations were deter-
mined before treatment of the first patient. Base-
The New England Journal of Medicine 
Downloaded from nejm.org on April 22, 2017. For personal use only. No other uses without permission. 
 Copyright © 2009 Massachusetts Medical Society. All rights reserved. 
Th e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 361;4 nejm.org july 23, 2009360
line magnetic resonance imaging (MRI) and au-
diology were performed within 1 month before 
starting treatment. Clinical evaluation, which in-
cluded a physical examination, complete blood 
count, blood chemical analysis, and urinalysis, 
was performed every 2 to 4 weeks during treat-
ment. Tumor response was monitored with the 
use of serial MRI scanning at clinical visits at 
months 1, 3, and 6 and every 3 months thereaf-
ter. Tumor volumetric analysis was performed as 
described previously.17 To investigate whether 
tumor shrinkage might be related, in part, to a 
decrease in intratumoral vasogenic edema, we sub-
sequently determined the mean apparent diffu-
sion coefficient (a measure of the magnitude of 
diffusion of water molecules within tissue and a 
marker of edema on imaging with MRI18) with-
in vestibular schwannomas at baseline. Dynam-
ic contrast-enhanced MRI (DCE-MRI) was per-
formed in Patient 6 to evaluate changes in blood 
flow and vascular permeability after treatment.18 
Hearing response was monitored with the use of 
serial audiologic evaluations, including determi-
nation of pure-tone thresholds and word-recog-
nition scores (for details, see the Supplementary 
Appen dix).19,20 Data regarding toxic effects were 
collected monthly during routine clinic visits, 
and adverse events were scored according to the 
Common Terminology Criteria for Adverse Events, 
version 3.0.
Definitions of imaging and Hearing 
Responses
We established definitions of imaging and hear-
ing responses after noting a clinical benefit in 
the first patient. An imaging response was de-
fined as a decrease of at least 20% in tumor vol-
ume, as compared with the pretreatment base-
line.21 Volumetric changes of 15% or 20% have 
been used to define response and progression in 
early-phase trials involving patients with plexi-
form neurofibromas associated with neurofibro-
matosis type 1.22,23
A hearing response was defined as a signifi-
cant increase in the word-recognition score, as 
compared with the baseline score.24 Patients 
were eligible for a hearing response if their pre-
treatment word-recognition score allowed for 
hearing improvement above the upper limit of 
the critical-difference threshold (i.e., a word-
recognition score of 94% or less). Patients with 
surgically disrupted auditory nerves were not 
eligible for a hearing response. We used pub-
lished guidelines25 to determine significant dif-
ferences between word-recognition scores to com-
pare each patient’s scores after treatment with 
baseline values.
Study Oversight
The institutional review board at Massachusetts 
General Hospital approved the retrospective chart 
review and tumor-specimen collections. All pa-
tients provided written informed consent for 
treatment. The authors vouch for the complete-
ness and veracity of the data and data analyses. 
Bevacizumab was provided as part of clinical 
care; Genentech, the maker of bevacizumab, had 
no role in the study.
Statistical Analysis
For analyses of morphologic features, microvas-
cular density, and measures of diameter and pe-
rimeter, we used Bartlett’s test for the equality of 
multiple variances to analyze between-group dif-
ferences in variance. Analysis-of-variance esti-
mate models were then built and appropriate 
post hoc testing was performed on the basis of 
Bartlett’s test results. For measures with equal 
variances, Tukey’s test was used. For measures 
with unequal variances, the Games–Howell test 
was used. A P value of less than 0.05 was consid-
ered to indicate statistical significance.
R esult s
Immunohistochemical Analyses
In normal peripheral nerves, the ligands VEGF, 
semaphorin 3A, semaphorin 3F, and the recep-
tors VEGFR-2 and neuropilin-1 were consistently 
expressed in both Schwann cells and vascular 
endothelial cells; neuropilin-2 was seen in all 
Schwann cells but in less than 5% of blood ves-
sels (Fig. 1A, and Fig. 1 in the Supplementary 
Appendix). In the schwannomas, tumor cells had 
expression patterns of VEGF, neuropilin-1, and 
neuropilin-2 that were similar to those in normal 
nerve. In contrast, VEGFR-2 was expressed in 
about half of all schwannomas, and semaphorin 
3A and semaphorin 3F were expressed in only 
20% of schwannomas and at reduced intensity 
(Fig. 1A and 1B, and Fig. 2 in the Supplementary 
Appendix).
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VEGFR-2 was found in 32% of vessels in tu-
mors associated with neurofibromatosis type 2 
and in sporadic tumors. In contrast, all vessels 
expressed neuropilin-1 (similar to normal nerve), 
and about 10% of vessels expressed neuropilin-2 
(Fig. 1C). Most tumor cells showed little or no 
expression of PDGFR-α or PDGFR-β. More than 
50% of tumor specimens expressed both PDGFR-α 
and PDGFR-β on the vascular endothelium, con-
sistent with an angiogenic phenotype (Fig. 3 in 
the Supplementary Appendix).
Morphometric analysis revealed that schwan-
nomas associated with neurofibromatosis type 2 
showed a greater microvascular density (22 ves-
sels per square millimeter) and a larger vessel 
diameter (mean, 14.2 μm), and perimeter (mean, 
91 μm) than normal nerve (with 18 vessels per 
square millimeter and a mean vessel diameter of 
7.9 μm and perimeter of 47 μm) (Fig. 1D).
Patients
The baseline characteristics of the 10 patients in 
the study are shown in Table 1. All patients were 
poor candidates for standard treatment, since 
eight were at high risk for complete hearing loss 
and one for bilateral lower cranial-nerve palsies, 
and one patient had declined surgery or radia-
tion. Patients 1 through 5 had been treated previ-
ously with erlotinib chemotherapy26 but stopped 
treatment because of either toxic effects (Patient 
1) or tumor growth (Patients 2 through 5).
Treatment
Six men and four women with a median age of 25 
years (range, 16 to 53) received intravenous beva-
cizumab at a dose of 5 mg per kilogram of body 
weight every 2 weeks. The median annual growth 
rate in tumor volume before treatment was 62% 
(range, 9 to 121). The median duration of treat-
ment was 12 months (range, 3 to 19), and six 
patients were followed for at least 1 year. Six pa-
tients continued to be treated with bevacizumab 
at the end of the study. Patient 1 stopped treat-
ment after 19 months because of slow growth of 
a vestibular schwannoma, which caused brain-
stem compression; the tumor was subsequently 
resected. Patient 5 discontinued bevacizumab 
temporarily as she awaited surgical removal of a 
nonvestibular schwannoma. Patient 7 stopped 
bevacizumab after 3 months because of progres-
sive growth of a spinal meningioma; he died of 
complications after surgery to resect the tumor 
5 months later. Patient 8 stopped treatment after 
8 months because of progressive growth of a ves-
tibular schwannoma and hearing loss.
imaging Response
Of the 10 tumors, 9 shrank after bevacizumab 
treatment, and 6 had an imaging response (Ta-
ble 1, and Fig. 4 in the Supplementary Appendix). 
The median best response to treatment was 26% 
shrinkage (range, 44% shrinkage to 32% growth). 
Of six tumors that had an objective imaging re-
sponse, the response was maintained in four tu-
mors at the last imaging follow-up 11 to 16 months 
after the initiation of treatment. Three tumors 
remained stable (i.e., ranging from a 19% reduc-
tion to a 19% increase in volumetric growth, as 
compared with baseline) during bevacizumab 
treatment, and one patient had an increase in 
tumor volume of 32%.
A strong correlation was observed between 
the mean apparent diffusion coefficient at base-
line within tumors and the percent decrease in 
volume at 3 months (Pearson’s r correlation, 
−0.87; r 2 = 0.75; P = 0.001) (Fig. 2A). In the single 
patient with complete DCE-MRI data (Patient 6), 
a measure of blood flow and vascular permeabil-
ity decreased by 68%, tumor blood volume de-
creased by 77%, tumor blood flow decreased by 
51%, mean transit time decreased by 9%, and the 
average vessel size decreased by 70% at 3 months 
(Fig. 2B). Twelve months after the initiation of 
treatment, measures of blood flow and vascular 
permeability continued to fall. Although the 
amount of gadolinium enhancement decreased 
over time, the enhancement pattern within ves-
tibular schwannomas did not change noticeably 
during treatment (Fig. 2C).
Hearing Response
Seven patients were considered eligible for a hear-
ing response. Of the other three patients, two had 
normal hearing ipsilateral to index vestibular 
schwannomas at baseline (and thus could not 
improve), and one had undergone surgical resec-
tion of both auditory nerves. A hearing response 
was observed in four of seven eligible patients 
(57%) (Fig. 5 in the Supplementary Appendix). 
The hearing benefit of bevacizumab was large 
for Patient 2, whose word-recognition score in-
creased from 8% to 98%, and for Patient 3, whose 
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word-recognition score increased from 34% to 
76%. Both Patient 2 and Patient 3 regained useful 
hearing, and they were able to resume school and 
work, respectively. Patient 4, whose word-recog-
nition score increased from 0% to 40%, reported 
better speech-reading (lip-reading), and Patient 5, 
whose word-recognition score increased from 
76% to 94%, also reported improvement in face-
to-face conversation. Patients with a hearing re-
sponse showed progressive improvement in word 
recognition, which began about 8 weeks after the 
initiation of treatment and continued to improve 
for as long as 16 months (Fig. 5 in the Supple-
mentary Appendix). Among the four patients who 
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had a hearing response, the result was durable 
for 11 to 16 months.
Of the three patients who did not have a hear-
ing response, Patient 1 had had no word recog-
nition for at least 8 months before treatment, 
Patient 8 had a decline in word recognition (44% 
to 16%) after starting treatment despite initial 
tumor shrinkage, and Patient 10 had stable hear-
ing despite a sustained reduction in tumor vol-
ume. Although Patient 1 did not have a hearing or 
an imaging response, he had clinical improve-
ment that may have been related to treatment. 
Before treatment, he was receiving hospice care 
because of intractable headache and vomiting 
associated with critical brain-stem compression. 
Within 4 weeks after starting therapy, his head-
aches and vomiting resolved, and he returned to 
high school. He remained clinically improved for 
19 months of treatment but then required resec-
tion of his vestibular schwannoma for tumor 
growth. Four of five patients reported subjective 
improvement in baseline tinnitus, and one noted 
no change.
Adverse Effects
A total of 21 grade 1 or 2 adverse events were 
reported, including increased levels of aspartate 
aminotransferase (4 events) and alanine amino-
transferase (3 events), proteinuria (3 events), hyper-
tension (2 events), delayed wound healing (2 events), 
hyperkalemia (2 events), hyperbilirubinemia (2 
events), uterine bleeding (1 event), hypocalcemia 
(1 event), hypophosphatemia (1 event), and hypo-
magnesemia (1 event). Two patients had infected 
vascular access ports requiring removal. In this 
small sample of patients, no patients had throm-
boembolic events, hemorrhage, congestive heart 
failure, gastrointestinal perforation, or reversible 
posterior leukoencephalopathy. No patient dis-
continued treatment because of adverse events, 
and no grade 3 or 4 adverse events were reported.
Discussion
Our study showed that bevacizumab treatment 
was followed by clinically meaningful hearing 
improvement, tumor-volume reduction, or both in 
some, but not all, patients with neurofibromato-
sis type 2 who were at risk for complete hearing 
loss or brain-stem compression from growing 
vestibular schwannomas. Our findings confirm 
that VEGF is produced by schwannoma tumor 
cells10-14 and suggests that this growth factor 
may participate in tumor growth and hearing loss 
associated with vestibular schwannomas. The 
imaging findings indicate that the mean apparent 
diffusion coefficient at baseline might be a po-
tential marker for volumetric response to anti-
VEGF therapy. The DCE-MRI data, though limit-
ed, further suggest that bevacizumab normalizes 
the function of tumor vessels and potentially re-
stores a more normal blood–nerve barrier.
These findings have implications for patients 
Figure 1 (facing page). Angiogenic Profile of Vestibular 
Schwannomas.
Panel A shows immunohistochemical analysis of mem-
bers of the vascular endothelial growth factor (VEGF) 
pathway in normal peripheral nerve and schwannoma. 
In normal nerve, staining for VEGF highlights Schwann 
cells (arrows), and staining for VEGF receptor 2 (VEGFR-2) 
highlights vessels (arrowheads). Staining for neuropilin-2 
(NRP-2) and semaphorin 3F (SEMA-3F) highlights 
Schwann cells in normal nerve. In schwannomas, VEGF 
staining highlights tumor cells (arrowhead) and blood 
vessels (arrow); VEGFR-2 staining highlights some ves-
sels (arrowheads), whereas others remain unstained (ar-
rows). Tumor cells stain diffusely for NRP-2 but not for 
SEMA-3F. In all panels, brown staining shows positivity 
for the given antigen, and blue labels the nuclei, with 
the letter A denoting axon, the letter M myelin, and the 
letter S Schwann cell. Panel B shows the percentage  
of samples with expression of more than 1 on a scale 
of 0 (no staining) to 3 (strong staining) for the known 
members of the VEGF pathway (ligands and receptors). 
SEMA-3F and SEMA-3A are expressed in all nerve roots 
(3 intensity). In samples from patients with neurofibro-
matosis type 2 (NF2), 58% of the tumors have completely 
negative staining for SEMA-3F, and 22% are negative for 
SEMA-3A. In samples from patients with sporadic tumors, 
44% of tumors are negative for SEMA-3F, and 33% are 
negative for SEMA-3A. Since none of the samples were 
scored as 2 or 3, no bar is shown for SEMA-3A. Panel C 
shows the quantification of the number of vessels per 
square millimeter expressing VEGFR-2 and NRP-2 in 
vestibular schwannomas associated with neurofibroma-
tosis type 2 and sporadic vestibular schwannomas. CD31 
was used to count the total number of vessels per square 
millimeter. There were no significant differences between 
tumors associated with neurofibromatosis type 2 and 
sporadic tumors. Panel D shows statistical analysis of 
the morphometric measures. Diameter, perimeter, and 
microvascular density were all significantly smaller for 
the 470 vessels analyzed in normal peripheral nerve 
roots than in either schwannomas associated with neu-
rofibromatosis type 2 (1215 vessels from 20 patients) or 
sporadic schwannomas (2104 vessels from 17 patients). 
The perimeters (or surface area, data not shown) were 
significantly larger in tumors associated with neurofi-
bromatosis type 2 than in sporadic tumors.
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with neurofibromatosis type 2 and for the study 
of vestibular schwannoma biology. First, the re-
duced expression of VEGFR-2 on tumor vessels 
suggested that interfering with the function of 
VEGF receptors might be less effective than tar-
geting VEGF directly, which prompted our choice 
of bevacizumab for treatment. Our data suggest 
that the current understanding of VEGF-mediat-
ed angiogenesis — that VEGF is secreted by 
tumor cells and then binds to and activates 
VEGFR-2 on endothelial cells — may be more 
complex in schwannomas, in which vessels ex-
press different VEGF receptors. Further work is 
needed to understand the role of the sema-
phorin–neuropilin axis in these tumors.
Second, VEGF inhibition can lead to modest 
but relevant decreases in the volume of vestibu-
lar schwannomas. This effect is notable, given 
the lack of sensitivity of benign nervous-system 
tumors to standard cytotoxic chemotherapy. Third, 
in some patients, VEGF inhibition can lead to a 
relatively rapid (<12 weeks) improvement in hear-
ing, as reflected by word-recognition scores, with 
sustained improvement for up to 16 months. Ob-
servational studies have shown that word-recog-
nition scores deteriorate over time in patients 
with vestibular schwannomas and that signifi-
cant improvement is not expected.27 We posit 
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Figure 2. Changes in Magnetic Resonance Imaging 
(MRI) Measures during Treatment with Bevacizumab.
Panel A shows the correlation between mean apparent 
diffusion coefficients (ADCs) at baseline and subse-
quent changes in tumor volume for the 10 patients after 
3 months of treatment with bevacizumab. Panel B shows 
dynamic contrast-enhanced MRIs of Patient 6, with mea-
sures of blood flow and vascular permeability indicat-
ing the permeability of vestibular schwannomas (with 
the most permeable areas shown in white and the least 
permeable areas in dark red). At baseline, permeability 
is high for both tumors but decreases progressively 
during 12 months of treatment, as shown by the values 
beneath the images. Panel C shows representative cra-
nial T1-weighted MRI scans of Patient 2 after the admin-
istration of contrast material at baseline (left) and after 
9 months of treatment (right). T2-weighted scans are 
also shown at the same time points. The overall decrease 
in tumor volume (30%) can be seen by comparing the 
tumor outline at baseline (yellow line) with the outline 
after 3 months of treatment with bevacizumab (red 
line). The enhancement pattern in vestibular schwan-
nomas did not change noticeably during treatment 
with bevacizumab.
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that improvement is due to a reduction in intra-
neural edema, as well as tumor shrinkage. This 
assertion is supported by the time course of 
hearing improvement, the correlation between 
the mean apparent diffusion coefficient and tu-
mor shrinkage, and the changes in intratumoral 
vascular permeability, as seen on DCE-MRI. This 
mechanism is consistent with the vascular-
normalization hypothesis28 and previous studies 
of anti-VEGF therapy in malignant brain tu-
mors.18,29
To date, four of our six patients with an imag-
ing response and all four patients with a hearing 
response have continued to respond to therapy 
for 11 to 16 months. This suggests that response 
to anti-VEGF therapy can be durable for progres-
sive vestibular schwannomas associated with 
neurofibromatosis type 2. In contrast, the median 
time to progression for recurrent glioblastoma 
treated with antiangiogenic therapy is about 16 
weeks.18,30 Patients with benign tumors who 
benefit from anti-VEGF therapy present unique 
clinical challenges: they may have prolonged sur-
vival during which unanticipated delayed toxic 
effects could become manifest, and the implica-
tions of stopping therapy are unknown, with the 
potential for rebound tumor growth when mono-
clonal treatment is stopped.18
Although the need for an effective medical 
therapy for patients with neurofibromatosis type 
2 is clear, the risk of toxic effects deserves care-
ful consideration. In our preliminary experience, 
toxic effects were limited to grade 1 or 2 adverse 
events during follow-up of up to 16 months, 
which is not long in comparison with the ex-
pected survival of these young patients. The ab-
sence of many common toxic effects of bevaci-
zumab in our patients may have reflected their 
relative youth, the lack of other medical condi-
tions, and the small number of patients who 
were treated.
Our results show an interesting biologic effect 
of bevacizumab treatment on vestibular schwan-
nomas associated with neurofibromatosis type 2. 
However, we treated only patients with neurofi-
bromatosis type 2 who were at imminent risk for 
severe neurologic consequences and not those 
with less advanced symptoms or patients with 
sporadic vestibular schwannomas. Additional re-
search will be necessary to determine the opti-
mal drug regimen, duration, and adverse-effect 
profile for long-term anti-VEGF therapy for ves-
tibular schwannomas associated with neurofibro-
matosis type 2.
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